These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20370683)

  • 1. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.
    Kenessey I; Keszthelyi M; Krámer Z; Berta J; Adám A; Dobos J; Mildner M; Flachner B; Cseh S; Barna G; Szokol B; Orfi L; Kéri G; Döme B; Klepetko W; Tímár J; Tóvári J
    Curr Cancer Drug Targets; 2010 May; 10(3):332-42. PubMed ID: 20370683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Met is a potentially new therapeutic target for treatment of human melanoma.
    Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
    Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
    Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
    Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation.
    Kucerova L; Demkova L; Skolekova S; Bohovic R; Matuskova M
    BMC Cancer; 2016 May; 16():308. PubMed ID: 27175734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.
    Hou J; Dong J; Sun L; Geng L; Wang J; Zheng J; Li Y; Bridge J; Hinrichs SH; Ding SJ
    J Transl Med; 2011 May; 9():64. PubMed ID: 21575221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth.
    Inagaki Y; Qi F; Gao J; Qu X; Hasegawa K; Sugawara Y; Tang W; Kokudo N
    Biosci Trends; 2011; 5(2):52-6. PubMed ID: 21572247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of motogenic signal in human melanoma cells].
    Kenessey I
    Magy Onkol; 2011 Mar; 55(1):55-8. PubMed ID: 21617791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
    Berthou S; Aebersold DM; Schmidt LS; Stroka D; Heigl C; Streit B; Stalder D; Gruber G; Liang C; Howlett AR; Candinas D; Greiner RH; Lipson KE; Zimmer Y
    Oncogene; 2004 Jul; 23(31):5387-93. PubMed ID: 15064724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
    Koon EC; Ma PC; Salgia R; Welch WR; Christensen JG; Berkowitz RS; Mok SC
    Int J Gynecol Cancer; 2008; 18(5):976-84. PubMed ID: 18021219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
    Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA
    Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
    Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
    Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
    Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
    Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.
    Davis IJ; McFadden AW; Zhang Y; Coxon A; Burgess TL; Wagner AJ; Fisher DE
    Cancer Res; 2010 Jan; 70(2):639-45. PubMed ID: 20068147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of c-Met inhibitor SU11274 on human colon cancer cell growth.
    Gao SH; Liu C; Wei J; Feng Y
    Chin Med J (Engl); 2013 Jul; 126(14):2705-9. PubMed ID: 23876900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.
    Gao W; Bing X; Li M; Yang Z; Li Y; Chen H
    Med Oncol; 2013 Jun; 30(2):546. PubMed ID: 23536000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
    Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
    Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
    Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
    Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells.
    Ayoub NM; Bachawal SV; Sylvester PW
    Cell Prolif; 2011 Dec; 44(6):516-26. PubMed ID: 21973114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
    Seiwert TY; Jagadeeswaran R; Faoro L; Janamanchi V; Nallasura V; El Dinali M; Yala S; Kanteti R; Cohen EE; Lingen MW; Martin L; Krishnaswamy S; Klein-Szanto A; Christensen JG; Vokes EE; Salgia R
    Cancer Res; 2009 Apr; 69(7):3021-31. PubMed ID: 19318576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
    Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
    Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.